Please assess the completion status of the following clinical trial:

Trial Title: Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All of the following:~* Patient must have non-M3 AML or MDS~* An adverse risk karyotype defined by:~  * Complex karyotype by cytogenetics, or~ * Deletion of all or part of chromosome 5, 7, 12, or 17 defined by FISH or cytogenetics, or~ * Somatic TP53 mutation~All of the following:~1. Patient must have an ECOG performance status ≤ 2.~2. Patient must have \>10% disease burden measured by cytomorphology, flow cytometry, or cytogenetics.~3. Patient must have peripheral white blood cell count \< 50,000/mcl.~4. Patient must have adequate organ function, defined as:~   1. Total bilirubin \< 1.5 x ULN~  2. AST/ALT \< 2.5 x ULN~  3. Serum creatinine \< 2.0 x ULN~5. Patient must have undergone ≤ 2 cycles of prior hypomethylating agent (decitabine or azacitidine).~6. Patient must be enrolled in HRPO# 201011766 (Tissue Acquisition for Analysis of Genetic Progression Factors in Hematologic Diseases).~7. Patient must be \> 18 years of age.~8. Patient must be able to understand and willing to sign an IRB-approved written informed consent document.~Exclusion Criteria:~* Patient must not be pregnant or nursing~* Patient must not have acute promyelocytic leukemia or t(15;17) observed by FISH.~* Patient must not have known central nervous system (CNS) leukemia~* Patient must not have a history of positive human immunodeficiency virus (HIV) serology~* Patient must not have a history of positive hepatitis C serology~* Patient must not have undergone prior allogeneic stem cell transplant~* Patient must not have any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, ongoing or active graft-versus-host disease (GVHD), congestive heart failure of New York Heart Association (NYHA) class 3 or 4, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements~* Patient must not have had radiation therapy within 14 days of enrollment~* Patient must not have received any chemotherapy within 21 days of enrollment and any acute treatment-related toxicities must have returned to baseline. Patients may be receiving hydrea at time of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): Patients receive decitabine IV over 1 hour on days 1-10 of a 28-day cycle. Treatment continues for 2 cycles. Patients then receive decitabine IV over 1 hour on days 1-10, 1-5, or 1-3 (depending on response). Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).